Kaprin Ivan Andreevich Biography

Ipsen Ipsen in the world of Ipsen is an international group of specialized biotechnological companies, which implements solutions in the field of improving the quality of life of patients and creating innovative drugs to treat diseases that cause disability. The group was founded in the year and works in 37 countries, numbering about 5.7 thousand employees around the world.

In the portfolio of Ipsen - 20 drugs in the field of oncology, neurology, rare diseases and general therapy. Additional information about Ipsen is presented on the website www. The company's portfolio is represented by 10 drugs used in general therapeutic practice, in the field of specialized assistance, including oncology, neurology, rare diseases and aesthetic medicine.

The company's staff is near employees. Russia leads the Closure Ipsen in the CIS, consisting of 10 countries. You can find out more about IPSen's activities in Russia on the website www. As a leading international pharmaceutical company, we use the latest scientific achievements and digital technologies in creating innovative drugs to solve the most acute medical and social problems.

Over millions of people around the world receive our drugs, and we are constantly working on finding innovative solutions to increase patients of patients to the necessary therapy. Address:, Moscow, Leningradsky Ave., 70 phone: website: www. The mission of Eisai is to pay the main attention to patients and their relatives principle of Human Health Care, HHC, to increase the efficiency of healthcare, observing the highest legal and ethical standards of activity.

Eisai has been striving for significant progress in the field of clinical research in oncology, based on scientific knowledge and experience, and has resources for the search, preclinical and developing new low molecular weight drugs, therapeutic vaccines, biological drugs and drugs for maintaining therapy for various oncological diseases. Additional information is presented on the www website.

Moscow, st. The unification of the pharmaceutical and diagnostic units allows Rosh to be one of the leaders in the field of personalized medicine - a strategy aimed at developing effective medical solutions for patients, taking into account the individual characteristics of each. The company is also one of the leaders in the field of in vitro diagnosis and histological diagnosis of cancer, as well as a pioneer in the field of self -control of diabetes.

Throughout its history, it continues to look for new opportunities for the prevention, diagnosis and treatment of diseases and makes a significant contribution to public development. The company also seeks to improve patients with medical innovation, working with all interested parties. More than 30 Roche drugs, including vital antibiotics, antimlarial and antitumor drugs, are included in the approximate lists of the main drugs of the WHO.

In addition, for 10 years in a row, Rosh has been recognized as a leader in the field of pharmaceuticals, biotechnology and biological sciences in terms of sustainability of the Dow Johns index. The Rosh Group of Companies, whose headquarters is located in Basel, Switzerland, has representative offices in more than in the countries of the world. The company has more than 94 people.

In the year, Rosh investments in research and development amounted to 11 billion Swiss francs. Additional information about Rosh in Russia can be obtained on the website of www. Moscow, Pipe Square, House 2 Phone: Site: www.